Recommended Pages at press.bayer.com
BAYNEWS - The Bayer Press Server - Bayer Schering Pharma Initiates Phase III Trial of Regorafenib in Metastatic Colorectal Cancer
press.bayer.com — “BAYNEWS - The Bayer Press Server - Bayer Schering Pharma Initiates Phase III Trial of Regorafenib in Metastatic Colorectal Cancer” View full resource at press.bayer.com
Most Recently Shared on May 7, 2010 at 2:19 pm By:
eyeonfda Pharma and Health Lawyer
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib in Metastatic Colorectal Cancer - http://ow.ly/1Ick1
BAYNEWS - The Bayer Press Server - Bayer CropScience supports worldwide battle against malaria
press.bayer.com — “BAYNEWS - The Bayer Press Server - Bayer CropScience supports worldwide battle against malaria” View full resource at press.bayer.com
Most Recently Shared on April 23, 2010 at 1:16 pm By:
eyeonfda Pharma and Health Lawyer
Bayer CropScience develops enhanced mosquito nets against malaria transmission - http://ow.ly/1Caa8
BAYNEWS - The Bayer Press Server - Bayer MaterialScience unites its biomaterials products under the new trade name Baymedix
press.bayer.com — “BAYNEWS - The Bayer Press Server - Bayer MaterialScience unites its biomaterials products under the new trade name Baymedix” View full resource at press.bayer.com
Most Recently Shared on March 18, 2010 at 1:21 pm By:
eyeonfda Pharma and Health Lawyer
Bayer MaterialScience unites its biomaterials products under the new trade name Baymedix® - http://ow.ly/1nMBC
BAYNEWS - The Bayer Press Server - FDA Grants Orphan Drug Status to Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
press.bayer.com — “BAYNEWS - The Bayer Press Server - FDA Grants Orphan Drug Status to Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis” View full resource at press.bayer.com
Most Recently Shared on March 11, 2010 at 2:36 pm By:
eyeonfda Pharma and Health Lawyer
Bayer - FDA Grants Orphan Drug Status to Ciprofloxacin Dry Powder Inhaler for Treatment of Cystic Fibrosis - http://ow.ly/1h2aa
BAYNEWS - The Bayer Press Server - Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis
press.bayer.com — “BAYNEWS - The Bayer Press Server - Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis” View full resource at press.bayer.com
Most Recently Shared on January 25, 2010 at 9:44 pm By:
eyeonfda Pharma and Health Lawyer
Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis - http://ow.ly/10kIc
BAYNEWS - The Bayer Press Server - Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
press.bayer.com — “BAYNEWS - The Bayer Press Server - Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE” View full resource at press.bayer.com
Most Recently Shared on December 6, 2009 at 3:54 pm By:
eyeonfda Pharma and Health Lawyer
Bayer Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban 4 VTE - http://ow.ly/Jej5
BAYNEWS - The Bayer Press Server - Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
press.bayer.com — “BAYNEWS - The Bayer Press Server - Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer” View full resource at press.bayer.com
Most Recently Shared on October 23, 2009 at 1:22 pm By:
eyeonfda Pharma and Health Lawyer
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer - http://bit.ly/2XoUmJ
BAYNEWS - The Bayer Press Server - Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
press.bayer.com — “BAYNEWS - The Bayer Press Server - Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients” View full resource at press.bayer.com
Most Recently Shared on September 22, 2009 at 1:28 pm By:
eyeonfda Pharma and Health Lawyer
Data from Bayer on Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) in Kidney Cancer Patients http://bit.ly/3r3lkJ
BAYNEWS - The Bayer Press Server - Phase III Trial Started to Evaluate Combination Therapy of Nexavar and Tarceva in Patients with Liver Cancer
press.bayer.com — “BAYNEWS - The Bayer Press Server - Phase III Trial Started to Evaluate Combination Therapy of Nexavar and Tarceva in Patients with Liver Cancer” View full resource at press.bayer.com
Most Recently Shared on May 28, 2009 at 1:42 pm By:
eyeonfda Pharma and Health Lawyer
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer - http://bit.ly/14vhJ9
